explore -WSS

explore

author：comprehensive 2025-10-01 12:36:02 - browse：29

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

WSS

FDA poised to publish guidelines for clinical trial diversity

U.K. researchers warn about biases in medical devices, algorithms

Questions and answers about ramping up H5N1 bird flu vaccine

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Addressing health care workers' trauma can help fight burnout

UnitedHealth increases loan offers after Change Healthcare outage

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Liver decline slowed by off

Drug repurposing or repositioning? The language matters

Addressing health care workers' trauma can help fight burnout

The high cost of giving birth even with insurance

Investigation reveals sickle cell patients pressured into sterilizations

Supreme Court strikes down use of affirmative action

Methadone treatment changes are coming. Do they go far enough?

Sports medicine is finally prioritizing gender equality

Baby aspirin cuts fat buildup in liver disease patients, in small study

Wikipedia

Colonoscopy prep: Liquid

Investigation reveals sickle cell patients pressured into sterilizations

As a primary care physician, here's how I hope to partner with AI

Colonoscopy prep: Liquid

As a primary care physician, here's how I hope to partner with AI

Study finds gene variants tied to breast cancer risk in Black women

focus

leisure time

leisure time

hotspot